

## New Clostridium difficile pathway now in production

By: April Yarbrough, PharmD, BCPS  
ID/ASP Clinical Pharmacist

Children's of Alabama c. diff pathway should be in production in I-connect by November 2019. Below are a few helpful tips to know for how to navigate the order set.

### What's new?

- There is a diagnostic/testing order set bundle and treatment bundle

Diagnostic Pathway	Treatment Pathway-Medication Order Set
<ul style="list-style-type: none"> <li>• Definition of C diff infection (CDI) and clinical symptoms (When to test) provided</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Discontinue all unnecessary antimicrobial agents (specifically agents such as clindamycin, 3<sup>rd</sup> generation cephalosporins and quinolones) as these may exaggerate CDI</b></li> </ul>
<ul style="list-style-type: none"> <li>• Risk factors for CDI (Who to test) listed</li> </ul>	<ul style="list-style-type: none"> <li>• It will be necessary to select <u>initial</u>, or <u>recurrent</u> disease, as well as <u>severity</u> to order the appropriate treatment of patients' CDI</li> </ul>
<ul style="list-style-type: none"> <li>• Hard stops or alerts for ordering screening                             <ul style="list-style-type: none"> <li>○ No patients under 1 year of age can be tested without ID approval</li> <li>○ Formed stool will be rejected by the lab</li> <li>○ If patients have been on treatment for CDI in last 7 days or have received a laxative medication in last 48 hours</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• <b>Vancomycin (oral)</b> is now the drug of choice for CDI for patients. It will be removed from browse except for this order set since there is not other indication for PO vancomycin.</li> <li>• Metronidazole can be considered for patients &lt;12 years of age with no medical complexities or underlying co-morbidities, and are not hospitalized with CDI related</li> </ul>

	illness.
<ul style="list-style-type: none"> <li>• Recommendations for ID consultation based on recurrence of disease, evaluation for FMT therapy.</li> </ul>	<ul style="list-style-type: none"> <li>• A second or greater recurrence of CDI should prompt an ID consult for consideration of alternative medication therapy (fidaxomicin) or evaluation for fecal microbiota transplant</li> </ul>

References:

- McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), *CID* 2018; 66(7):1–48.
- Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA), *ICHE* 2010; 31 (5): 431-455.
- Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of *Clostridium difficile* Infections. *Am J Gastroenterol* 2013; 108:478-498.